355 related articles for article (PubMed ID: 28348181)
1. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of cinacalcet withdrawal in Australian dialysis patients.
Ruderman I; Holt SG; Kirkland GS; Maslen S; Hawley CM; Oliver V; Krishnasamy R; Gray NA; Talaulikar GS; Nelson CL; Rajaram Y; Gock H; Au E; Elder GJ; Mainra R; Toussaint ND
Intern Med J; 2019 Jan; 49(1):48-54. PubMed ID: 29992701
[TBL] [Abstract][Full Text] [Related]
4. Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study.
Laurain E; Ayav C; Erpelding ML; Kessler M; Briançon S; Brunaud L; Frimat L
BMC Nephrol; 2014 Aug; 15():132. PubMed ID: 25123022
[TBL] [Abstract][Full Text] [Related]
5. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
8. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
9. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
12. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
14. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
15. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation.
Platt A; Wilson J; Hall R; Ephraim PL; Morton S; Shafi T; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
Am J Kidney Dis; 2024 Jan; 83(1):58-70. PubMed ID: 37690631
[TBL] [Abstract][Full Text] [Related]
17. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
18. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
19. Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital.
Sin HY
J Clin Pharm Ther; 2017 Oct; 42(5):607-614. PubMed ID: 28585333
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]